NEW YORK, NY, USA I June 02, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

NANTES, France I June 2, 2025 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” ...

BALLERUP, Denmark I June 03, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept ...

HOUSTON, TX, USA I June 2, 2025 I Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat ...

AMT-130 has been granted the FDA’s Regenerative Medicine Advance Therapy (RMAT) designation and Breakthrough Therapy designation, the first therapy for Huntington’s disease to receive an RMAT ...

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance ...

Abstract Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

– ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – ...

IMDELLTRA® (tarlatamab-dlle) U.S. Indication IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions ...

TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo ...

CHICAGO, IL, USA I June 2, 2025 I ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial ...